drugset / Trial / NCT01788774

Pharmacokinetic, Safety, and Tolerability Study of Risperidone ISM® at Different Dose Strengths

NCT01788774

Phase 1 Completed 36 enrolled Rovi Pharmaceuticals Laboratories
RandomizedParallel-groupOpen-labelTreatment

Summary

This clinical trial is designed to evaluate different dosages of risperidone ISM, a new long-acting injectable form.

Timeline

Start
2013-04
Primary completion
2014-02
Completion
2014-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Risperidone Other / unclassified 50 mg Intramuscular
Subject Risperidone Other / unclassified 75 mg Intramuscular
Subject Risperidone Other / unclassified 100 mg Intramuscular